Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.

Vertex's Chronic Pain Ambitions Hit Roadblock with LSR Data So much of Journavx's potential lies in chronic pain management. In December, Vertex revealed Phase 2 data evaluating Journavx in ...

A non-opioid pain medication made by Vertex Pharmaceuticals ... safe and effective alternatives to opioids for pain management." Vertex said that almost 10% of patients initially given opioids ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor ...

Vertex’s medicine could therefore be an “amazing” addition, he said, as it may offer some relief not only after surgery, but in everyday pain management as well. Journavx might dull ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective ...

The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...

we have the opportunity to change the paradigm of acute pain management and establish a new standard of care,” Vertex’s chief executive, Reshma Kewalramani, said in a statement. Soon after the ...

For Vertex these days, it’s all about the launches ... The measure increases access to non-opioid approaches to pain management in the hospital setting for those enrolled in Medicare.

“I believe suzetrigine could redefine the management of pain and become a foundational treatment option for people with all types of moderate-to-severe acute pain, where options aside from opioids ...